International policies and challenges on the legalization of traditional medicine/herbal medicines in the fight against COVID-19

Autor: Bert van Duijn, Min Gao, Yin Xiong, Ho-Young Choi, Frits van Horssen, Mei Wang
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Complementary Therapies
Review
Global Health
0302 clinical medicine
CDC
Centre for Disease Control
Health care
Legalization
HMs
herbal medicine
Policy Making
Drug Approval
TGA
Therapeutic Goods Administration
Traditional medicine
COVID-19
corona virus disease 2019
Policy
030220 oncology & carcinogenesis
TKM
traditional Korean medicine
AYUSH
Ayurveda
Yoga and Naturopathy
Unani
Siddha
Sowa Rigpa and Homeopathy
TCM
traditional Chinese medicine
medicine.medical_specialty
Resource (biology)
Medication history
TM
traditional medicine
WHO
The World Health Organization
Antiviral Agents
MHRA
Medicines and Healthcare products Regulatory Agency
03 medical and health sciences
Political science
EU
European Union
medicine
Herbal medicines
Humans
SARS
severe acute respiratory syndrome
Traditional knowledge
Healthcare Disparities
China
TURs
traditional use registrations
Pharmacology
business.industry
PIs
pattern identifications
Public health
COVID-19
COVID-19 Drug Treatment
WEU-MAs
well-established use marketing authorizations
030104 developmental biology
Harm
Medicine
Traditional
Plant Preparations
business
SARS-CoV
severe acute respiratory syndrome corona virus
Zdroj: Pharmacological Research
ISSN: 1043-6618
DOI: 10.1016/j.phrs.2021.105472
Popis: The coronavirus disease 2019 (COVID-19) has now rapidly spread around the world, causing an outbreak of acute infectious pneumonia. To develop effective and safe therapies for the prevention and treatment of COVID-19 has become the major global public health concern. Traditional medicine (TM)/herbal medicines (HMs) have been used to treat multiple epidemics in human history, which brings hope for the fight against COVID-19 in some areas. For example, in China, India, and South Korea with traditional medication history and theory, the governments issued a series of guidelines to support TM/HMs in the medication of COVID-19. In contrast, other countries e.g. North American and European governments are typically silent on these practices, unless to warn of possible harm and overselling. Such difference is due to the discrepancy in culture, history and philosophical views of health care and medication, as well as unharmonized policies and standards in the regulation and legalization of TM/HMs among different areas. Herein, we reviewed the responses and scientific researches from seven selected countries on the policies and legalization of TM/HMs to treat COVID-19, and also analyzed the major challenges and concerns to utilize the traditional knowledge and resource.
Graphical Abstract ga1
Databáze: OpenAIRE
Externí odkaz: